Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: data from an open-label, multicenter phase 2 basket study

2021 ◽  
pp. clincanres.1698.2021
Author(s):  
Yuan-Yuan Qu ◽  
Hai-Liang Zhang ◽  
Hongqian Guo ◽  
Hong Luo ◽  
Qing Zou ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase 2 ◽  
Open Label ◽  
Multicenter Phase

scholarly journals Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

2015 ◽  
Vol 16 (15) ◽  
pp. 1473-1482 ◽  
Author(s):  
Robert J Motzer ◽  
Thomas E Hutson ◽  
Hilary Glen ◽  
M Dror Michaelson ◽  
Ana Molina ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Multicentre Trial ◽  
Phase 2 ◽  
Open Label

A multicenter, open-label, single-arm, phase 2 study of the S1P inhibitor sonepcizumab (LT1009) in patients with previously treated metastatic renal cell carcinoma (mRCC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS4605-TPS4605
Author(s):  
Rupal Satish Bhatt ◽  
Sumanta Kumar Pal ◽  
Harry A. Drabkin ◽  
John D. Hainsworth ◽  
Andrew Dorr ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Previously Treated
Sign in / Sign up

Export Citation Format

Share Document